Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms
- 23 May 2013
- journal article
- Published by American Society of Hematology in Blood
- Vol. 121 (21), 4388-4395
- https://doi.org/10.1182/blood-2013-02-486050
Abstract
Key Points In MPL exon 10–mutated myeloproliferative neoplasms, the MPL-mutant allele burden varies considerably from about 1% to almost 100%. High mutation burdens originate from acquired copy-neutral loss of heterozygosity of chromosome 1p and are associated with marrow fibrosis.This publication has 40 references indexed in Scilit:
- Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burdenLeukemia, 2007
- An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptorBlood, 2006
- Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective studyThe Lancet, 2005
- European consensus on grading bone marrow fibrosis and assessment of cellularity.2005
- Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders.2005
- Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisCancer Cell, 2005
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersThe New England Journal of Medicine, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersThe Lancet, 2005
- The World Health Organization (WHO) classification of the myeloid neoplasmsBlood, 2002